Vitamin B3 (niacin) for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests if nicotinic acid (a form of vitamin B3) can help people with mild to moderate Alzheimer's disease. It involves taking a daily pill, having a lumbar puncture, and regular check-ups to see if the vitamin improves thinking and memory.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 85 years old.
- You have a diagnosis of Alzheimer's disease with mild to moderate dementia (MMSE score between 14 and 24).
- You are on a stable dose of Alzheimer's medications (like donepezil, rivastigmine, or memantine) for at least 30 days, or you are not taking any of these.
- You have a family member or friend who sees you at least 3 times a week and can help you follow the study rules.
- You have had an MRI or CT scan of your brain in the past year (or are willing to have one).
- You must be willing to have a lumbar puncture (spinal tap) as part of the study.
- You are not currently taking niacin supplements, multivitamins with niacin, or energy drinks containing niacin (or you can stop them for 4 weeks before starting).
- You do not have liver disease or elevated liver enzymes, and you are not taking blood thinners (except aspirin).
- You do not have a history of a major stroke or severe cerebrovascular disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking nicotinamide riboside (a form of niacin) affects early memory changes in people with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). It also uses passive wearable or sensor data (“digital biomarkers”) to measure changes over time.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This study tests whether taking melatonin for 3 months can improve brain structure and blood markers in people with memory problems or early Alzheimer's. It involves brain scans and simple tests of thinking and physical function.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.